Harsh, Veronica
Clayton, Anita H.
Article History
First Online: 14 March 2018
Compliance with Ethical Standards
:
: Veronica Harsh declares no conflict of interest. Anita H. Clayton reports grants from Auspex Pharmaceuticals, Genomind, Inc., Trimel Biopharma, grants and personal fees from Forest (now Actavis), Palatin Technologies, Pfizer, Inc., and Takeda, and personal fees from Arbor Scientia, Lundbeck, Naurex, Ostuka, Roche, S1 Biopharmaceuticals, Sprout, a division of Valeant. Dr. Clayton also owns shares in S1 Biopharmaceuticals and Euthmyics. Dr. Clayton has a patent Changes in Sexual Functioning Questionniare with royalties paid, a patent Guilford Publications with royalties paid, and a patent Ballantine Books/Random House with royalties paid and International Consultation for Sexual Medicine—Vice Chair: travel/accommodations/meeting expenses World Health Organization ICD-11 Advisory Meeting on Sexual Dysfunctions and Sexual Pain Disorders—Board Member/Presenter: travel/accommodations/meeting expenses.
: This article does not contain any studies with human or animal subjects performed by any of the authors.